ABLE, the Association of Biotechnology Led Enterprises, has announced the appointment of its first Director General, Nitin Deshmukh. He will take on this position in addition to his existing responsibilities as Director of a US based Venture Capital Fund, shortly launching its operations in India.

Nitin Deshmukh was until recently, Director, Private Equity, at Dresdner Kleinwort Capital. Prior to this, he served as Chief of Private Equity Investment at ICICI Ventures. During his thirteen years of private equity investment experience, Mr. Deshmukh has been involved with several investments in the life science sector: Sun Pharmaceuticals, Morepen Laboratories, Medicorp, Newland Laboratories, Ajanta Pharma and Intas Pharmaceuticals in the pharma sector and Avesthagen, Advanced Biochemicals, Biocon, Bangalore Genei and Syngene in the biotechnology segment. Prior to his association with Private Equity Banking, Nitin Deshmukh spent four years with CIPLA in various technical and management positions.

Nitin Deshmukh will bring to ABLE his vast experience of working closely with the life science sector especially in the area of investment and venture funding, said Ms. Kiran Mazumdar-Shaw, head, Vision Group on Biotechnology, government of Karnataka.